Objectives Immune checkpoint inhibitors (ICIs) targeting the cytotoxic T-lymphocyte-associated
protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) pathways have …

Background Interstitial lung disease is a known complication of rheumatoid arthritis, with a
lifetime risk of developing the disease in any individual of 7·7%. We aimed to assess the safety…

Objective. The aim was to study the prevalence, rate of appearance and severity of clinical
features in patients with different anti-synthetase syndrome (ASyS) autoantibodies. Methods. …

Objective This open‐label 12‐week study was conducted to evaluate the efficacy and safety
of tofacitinib, a JAK inhibitor, in treatment‐refractory active dermatomyositis (DM). Methods …

Objectives The aims of this study were to define the pattern of muscle involvement in
patients with immune-mediated necrotising myopathy (IMNM) relative to those with other …

Objective. To study disease severity and response to therapy in a large cohort of patients
with anti-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)-associated myositis. …

Objective Patients with immune‐mediated necrotizing myopathy (IMNM) often have
autoantibodies recognizing the signal recognition particle (SRP) or HMG‐CoA reductase (HMGCR). …

Objective Dermatomyositis ( DM ) patients typically present with proximal weakness and
autoantibodies that are associated with distinct clinical phenotypes. We observed that DM …

Objective Activation of the type 1 interferon (IFN1) pathway is a prominent feature of
dermatomyositis (DM) muscle and may play a role in the pathogenesis of this disease. However, the …

Purpose Among patients with autoimmune myositis, associated interstitial lung disease (MA-ILD)
is a known contributor of excess morbidity and mortality. Recent data on survival in …